A Nationwide Digital Multidisciplinary Intervention Aimed at Promoting Pneumococcal Vaccination in Immunocompromised Patients
Immunocompromised patients (IPs) are at high risk for infections, some of which are vaccine-preventable. The Israeli Ministry of Health recommends pneumococcal conjugate vaccine 13 (PCV13) and pneumococcal polysaccharide vaccine 23 (PPSV23) for IP, but vaccine coverage is suboptimal. We assessed the...
Main Authors: | Shirley Shapiro Ben David, Orna Shamai-Lubovitz, Vered Mourad, Iris Goren, Erica Cohen Iunger, Tamar Alcalay, Angela Irony, Shira Greenfeld, Limor Adler, Amos Cahan |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-08-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/11/8/1355 |
Similar Items
-
Vaccination Coverage among Immunocompromised Patients in a Large Health Maintenance Organization: Findings from a Novel Computerized Registry
by: Shirley Shapiro Ben David, et al.
Published: (2022-10-01) -
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidence
by: Erica Chilson, et al.
Published: (2020-11-01) -
Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece
by: George Gourzoulidis, et al.
Published: (2023-09-01) -
Pneumococcal Serotype Evolution and Burden in European Adults in the Last Decade: A Systematic Review
by: Rita Teixeira, et al.
Published: (2023-05-01) -
Assessing Public Health Impact of Four Pediatric Pneumococcal Conjugate Vaccination Strategies in the Netherlands
by: Michele Wilson, et al.
Published: (2023-06-01)